Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor

被引:0
|
作者
Surya P. Ayalasomayajula
Thomas H. Langenickel
Pierre Jordaan
Wei Zhou
Priyamvada Chandra
Diego Albrecht
Parasar Pal
Iris Rajman
Gangadhar Sunkara
机构
[1] Novartis Institutes for BioMedical Research,Drug Metabolism and Pharmacokinetics
[2] Novartis Pharma AG,Translational Medicine, Clinical Pharmacology and Profiling
[3] Novartis Healthcare Pvt Ltd,undefined
关键词
Angiotensin receptor neprilysin inhibitor; LCZ696; Pharmacokinetics; Renal impairment; Valsartan; Sacubitril;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1065 / 1073
页数:8
相关论文
共 50 条
  • [1] Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor
    Ayalasomayajula, Surya P.
    Langenickel, Thomas H.
    Jordaan, Pierre
    Zhou, Wei
    Chandra, Priyamvada
    Albrecht, Diego
    Pal, Parasar
    Rajman, Iris
    Sunkara, Gangadhar
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (09) : 1065 - 1073
  • [2] Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor
    Ayalasomayajula, Surya
    Langenickel, Thomas
    Pal, Parasar
    Boggarapu, Sreedevi
    Sunkara, Gangadhar
    CLINICAL PHARMACOKINETICS, 2017, 56 (12) : 1461 - 1478
  • [3] Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor–Neprilysin Inhibitor
    Surya Ayalasomayajula
    Thomas Langenickel
    Parasar Pal
    Sreedevi Boggarapu
    Gangadhar Sunkara
    Clinical Pharmacokinetics, 2018, 57 : 105 - 123
  • [4] Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor
    Surya Ayalasomayajula
    Thomas Langenickel
    Parasar Pal
    Sreedevi Boggarapu
    Gangadhar Sunkara
    Clinical Pharmacokinetics, 2017, 56 : 1461 - 1478
  • [5] LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
    Martin P Lefkowitz
    BMC Pharmacology and Toxicology, 16 (Suppl 1)
  • [6] Effect of food on the oral bioavailability of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
    Ayalasomayajula, Surya
    Langenickel, Thomas H.
    Chandra, Priya
    Wolfson, Edward D.
    Albrecht, Diego
    Zhou, Wel
    Pal, Parasar
    Rajman, Iris
    Sunkara, Gangadhar
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (12) : 1012 - 1018
  • [7] Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor (vol 56, pg 1461, 2017)
    Ayalasomayajula, Surya
    Langenickel, Thomas
    Pal, Parasar
    Boggarapu, Sreedevi
    Sunkara, Gangadhar
    CLINICAL PHARMACOKINETICS, 2018, 57 (01) : 105 - 123
  • [8] Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor
    Gan, Lu
    Langenickel, Thomas
    Petruck, Jesika
    Kode, Kiran
    Rajman, Iris
    Chandra, Priya
    Zhou, Wei
    Rebello, Sam
    Sunkara, Gangadhar
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (01): : 78 - 86
  • [9] Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects
    Akahori, Mizuki
    Ayalasomayajula, Surya
    Langenickel, Thomas
    Pal, Parasar
    Zhou, Wei
    Sunkara, Gangadhar
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (03) : 407 - 416
  • [10] Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects
    Mizuki Akahori
    Surya Ayalasomayajula
    Thomas Langenickel
    Parasar Pal
    Wei Zhou
    Gangadhar Sunkara
    European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42 : 407 - 416